



Ms. SACKY BAMFO JEMIMA

PID NO: P36180025877

Age: 49 Year(s) Sex: Female

Reference:

Sample Collected At:
GILEAD MEDICAL & DENTAL CENTER
HOUSE NO BALB NO C896/3,KANDA
HIGHWAY NORTH RIDGE,ACCRA-
14911.
014911

VID: 36180126539

Registered On:

18/01/2019 05:35 PM

Collected On:

18/01/2019

Reported On:

19/01/2019 12:17 PM

Investigation	Observed Value	Unit	Biological Reference Interval
CEA-Carcino Embryonic Antigen,Serum (Serum)	0.56	ng/mL	Non-Smoking: 0-2.5 Smoking: 0-5

Interpretation :

1. CEA (Carcinoembryonic Antigen), is an oncofetal glycoprotein and is expressed in normal mucosal cells and over expressed in adenocarcinoma, especially colorectal cancer.
2. CEA is used as a marker for monitoring colorectal and gastrointestinal carcinoma and is raised in carcinoma of lung ,breast,liver,pancreas ,prostate ,stomach and ovary .
3. Benign conditions which can elevate CEA include smoking, hepatic diseases, infections, inflammatory bowel disease, trauma, collagen vascular disease, renal disorders, pancreatitis, cirrhosis of the liver and peptic ulcer, hypothyroidism, chemotherapy and radiation. Although values are usually less than 10 ng/mL.
4. CEA is not an effective screening test for hidden (occult cancer since early tumors do not cause significant blood elevations .
5. A single test result is difficult to evaluate, but a number of tests, done weeks apart, shows trends in disease progression or regression .

Reference: Greg.L.Perkin. et.al. Serum Tumor Markers. American family physicians sep.2003 vol.68 no.6

Associated test : FDP DR-70 is a non-invasive blood test available for monitoring Colorectal Cancer therapy & assessing Post-therapy recurrence.

Reports to follow - Kindly await following pending reports :

Investigation :	Status
PAP smear Liquid based cytology (LBC)	Pending

-- End of Report --